Septerna discontinues SEP-786 Phase 1 clinical trial in hypoparathyroidism
Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...
Too Old to Operate6 天
Q&A: How Physicians Can Prevent Complications in Hypoparathyroidism Management, Part 1
Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...